Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte that is essential for nerve and muscle function, particularly the heart. It is supplied in various formulations for oral and intravenous administration. ## Primary Indications * Treatment and prevention of hypokalemia. * Potassium supplementation in patients receiving diuretics that deplete potassium. * Adjunct treatment in diabetic ketoacidosis. ## Adult Dosing * **Oral:** Doses vary significantly based on severity of deficiency and patient tolerance. Typical maintenance is 20-60 mEq/day divided into 1-4 doses. To treat hypokalemia, doses can range from 40-100 mEq/day. Maximum single oral doses are generally limited by GI tolerance, often around 20 mEq. * **Intravenous (IV):** Doses vary based on serum potassium level and severity of symptoms. * **Mild to moderate hypokalemia (serum K+ 2.5-3.4 mEq/L):** 10-20 mEq infused over 1-2 hours. * **Severe hypokalemia (serum K+ <2.5 mEq/L) or symptomatic:** 20-40 mEq infused via central line, typically over 2-4 hours, at a rate not exceeding 10 mEq/hour. * **Maximum IV infusion rate:** Generally 10-20 mEq/hour in peripheral lines and up to 40 mEq/hour in a central line with continuous ECG monitoring. * **Maximum single IV dose:** Typically 40 mEq, but may be higher in critical situations with appropriate monitoring. Total daily dose generally should not exceed 200 mEq without careful consideration. ## Pediatric Dosing * **Oral:** Doses are based on body weight. Typical maintenance: 1-2 mEq/kg/day, maximum 100 mEq/day. For treatment of hypokalemia: 2-5 mEq/kg/day, divided into doses. * **Intravenous (IV):** Doses are based on body weight and serum potassium levels. * **For routine replacement or mild hypokalemia:** 0.3-0.5 mEq/kg/dose, infused over 1-3 hours. Maximum 1 mEq/kg/hour. * **For severe hypokalemia:** May require higher doses and central line administration. * **Maximum concentration for peripheral IV:** 40 mEq/L. * **Maximum concentration for central IV:** 80 mEq/L. * **Maximum IV infusion rate:** 0.5 mEq/kg/hour, or up to 1 mEq/kg/hour in critical situations with continuous ECG monitoring. Local pediatric protocols should be consulted. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Dose reduction is necessary. Monitor serum potassium closely. IV administration should be significantly reduced or avoided. * **Hepatic Impairment:** No specific dose adjustment, but monitor electrolytes closely. ## Contraindications * Hyperkalemia. * Conditions where potassium levels are elevated, such as severe renal impairment or adrenal insufficiency. * Certain heart conditions (e.g., AV block) without a functioning pacemaker. * Untreated Addison's disease. * Digitalis intoxication with hyperkalemia. ## Adverse Effects * **Hyperkalemia:** The most serious adverse effect. Symptoms can include muscle weakness, fatigue, paresthesias, cardiac arrhythmias, and cardiac arrest. * **Gastrointestinal (Oral):** Nausea, vomiting, diarrhea, abdominal pain, GI bleeding, ulceration, perforation (especially with extended-release formulations). * **Venous irritation/phlebitis (IV):** Particularly with higher concentrations. * **Arrhythmias:** Can occur with both hypokalemia and hyperkalemia. ## Key Drug Interactions * **ACE inhibitors, ARBs, Potassium-sparing diuretics (e.g., spironolactone, amiloride), NSAIDs, Heparin:** Increased risk of hyperkalemia. * **Digoxin:** Hypokalemia increases risk of digoxin toxicity. Hyperkalemia can decrease digoxin effect. * **Neuromuscular blocking agents:** Potassium affects neuromuscular transmission; changes in potassium can alter the response. ## Monitoring * **Serum Potassium:** Essential, especially during IV therapy, dose titration, and in patients with renal impairment. Frequency depends on clinical status and route of administration. * **Renal function (BUN, creatinine):** Monitor periodically, especially in patients with underlying renal disease. * **ECG:** Especially with IV administration, rapid correction, or in patients with cardiac abnormalities. * **Signs and symptoms of hyperkalemia and hypokalemia.** ## Clinical Pearls * Oral potassium is often poorly tolerated due to GI side effects. Diluting liquid forms and taking with food can improve tolerance. Extended-release formulations may reduce GI irritation but can still cause issues. * IV potassium should *always* be administered with caution. Never give as a rapid IV bolus. * Correct hypokalemia cautiously, especially in patients with renal insufficiency or on ACE inhibitors/ARBs. * The American Heart Association/American College of Cardiology guidelines suggest a target serum potassium between 4.0-5.0 mEq/L in patients with ST-elevation myocardial infarction. *** **Disclaimer:** This information is intended for clinical decision-making support and does not replace a thorough review of the most current prescribing information, clinical guidelines, or consultation with a physician. Always verify drug information with official product monographs and institutional protocols.